A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Status:
Completed
Trial end date:
2018-02-20
Target enrollment:
Participant gender:
Summary
In the phase Ib, the primary purpose is to establish the maximum tolerated dose
(MTD)(s)/recommended phase ll dose (RP2D) and schedule of LEE011 and MEK162 orally
administered combination. Once the MTD(s)/RP2D have been determined for each tested schedule,
additional patients will be enrolled in the phase II portion of the study at the RP2D on the
chosen schedule in order to assess the anti-tumor activity of the combination in addition to
continued evaluation of safety.